NDAINJECTIONINJECTABLEPriority Review
Approved
Feb 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
KETALAR (ketamine hydrochloride) by Pfizer is ketalar, a racemic mixture of ketamine, is a non-selective, non-competitive antagonist of the n-methyl-d-aspartate (nmda) receptor, an ionotropic glutamate receptor. First approved in 1970.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KETALAR (ketamine hydrochloride) is a non-selective, non-competitive NMDA receptor antagonist approved since 1970 as an injectable anesthetic. It is primarily used for induction and maintenance of anesthesia, particularly in procedural sedation and pain management. The drug works by blocking glutamate signaling at NMDA receptors, producing rapid dissociative anesthesia with preserved airway reflexes.
LOE Approaching
As LOE approaches, expect defensive commercial strategy focused on retained market share and expanded indications rather than growth; core team likely stable or consolidating.
Mechanism of Action
KETALAR, a racemic mixture of ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. The major circulating metabolite of ketamine (norketamine) demonstrated activity at the same receptor with less affinity. Norketamine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KETALAR offers stable career footing in a mature, established product with global recognized brand equity and consistent demand across anesthesia and emerging psychiatric/pain markets. However, the LOE-approaching lifecycle limits growth trajectory; roles emphasize defensive market management, compliance, and evidence generation for off-label expansion rather than commercial launch excitement.
Brand Manager
Worked on KETALAR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.